ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- The Trial Enrollment Diversity Dashboard for Acute Leukemia Clinical Research: Intervention Development and Cohort Analysis.JCO oncology practice · 2025Trial
- Socioeconomic inequality in treatment of acute myeloid leukaemia (AML) in England, 2015-2022: A population-based study.British journal of haematology · 2026Article
- Review
- Article
- Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies.Future science OA · 2025Article
- Barriers and facilitators to representative acute leukemia trial participation at National Cancer Institute-designated comprehensive cancer centers.The oncologist · 2025Article
- Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024.Blood cancer journal · 2025Article
- Abatement of the Survival Cliff in Older Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in the United States.Journal of adolescent and young adult oncology · 2025Article
- The role of social, economic, and medical marginalization in cancer clinical trial participation inequities: A systematic review.Journal of clinical and translational science · 2025Review
- Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies.Current hematologic malignancy reports · 2024Review
- Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.Nature genetics · 2024Article
- Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia.Journal of the National Cancer Institute · 2024Article
- Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia.Blood cancer journal · 2023Article
- Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials.Blood advances · 2023Article
- Association of social deprivation with survival in younger adult patients with AML: an Alliance study.Blood advances · 2023Article
- A Process Framework for Ethically Deploying Artificial Intelligence in Oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
purposeRepresentativeness in acute leukemia clinical research is essential for achieving health equity. The National Cancer Institute's mandate for Comprehensive Cancer Centers (CCCs) to define and assume responsibility for cancer control and treatment across a geographic catchment area provides an enforceable mechanism to target and potentially remediate participatory inequities.
methodsWe examined enrollee characteristics across 15 Cancer and Leukemia Group B/Alliance cooperative group adult acute leukemia clinical trials (N = 3,734) from 1998 to 2013, including participation in optional companion biobanks. We determined enrollment odds by race-ethnicity for all participants adjusted for national incidence, and for those enrolled at CCCs adjusted for catchment area incidence. We modeled biobank participation by sociodemographics using logistic regression.
resultsNon-Hispanic (NH)-White patients were more likely to be enrolled than NH-Black, NH-Asian, or Hispanic patients (odds ratio [OR], 0.75, 0.48, and 0.44, respectively; all
conclusionAcute leukemia clinical research disparities are substantial and driven by structural trial enrollment barriers at CCCs. Real-time CCC access and enrollment monitoring is needed to better align research participation with local populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.